What is claimed is:

1. A compound represented by:



wherein

L^3 is selected from the group consisting of: C_1-C_6alkylene, -C(O)-, C_1-C_6alkylene-C(O)-, C(O)-C_1-C_6alkylene-, NR^a-C(O)-C_1-C_6alkylene-, C_1-C_6alkylene-O-C(O)-, -$S(O)_w$-, and C_1-C_6alkylene-$S(O)_w$-, wherein w is 0, 1, or 2, and wherein C_1-C_6alkylene is optionally substituted by one or two substituents selected from the group consisting of: halogen, hydroxyl, cyano, and an additional R^7, wherein when L^3 is -$S(O)_w$-, then R^7 is not H;

R^7 is selected from the group consisting of: H, phenyl, naphthyl, mono or bicyclic heteroaryl, and mono or bicyclic heterocyclyl, wherein the heteroaryl or the heterocyclyl has 1, 2 or 3 heteroatoms independently selected from O, S, or N; wherein R^7 is optionally substituted by one, two, three or four moieties independently selected from R^h;

R^a and R^b are independently selected, for each occurrence, from the group consisting of hydrogen and C_{1-3}alkyl; wherein C_{1-3}alkyl may optionally be substituted by one or more substituents selected from halogen, cyano, oxo, hydroxyl, heterocycle, and phenyl;

or R^a and R^b, when they occur together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring or a 9-10 membered bicyclic heterocycle or spirocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring or 9-10 membered bicyclic heterocycle or spirocycle may optionally be substituted by one or more substituents selected from the group consisting of halogen, cyano, oxo, C_{1-6}alkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), hydroxyl, -C(O)-C_{1-6}alkyl, -NH_2, and -NH-C(O)-C_{1-6}alkyl;

R^h is selected from the group consisting of: halogen, phenyl (optionally substituted by one, two, or three moieties each independently selected from R^c), phenyloxy (optionally substituted by one, two, or three moieties each independently selected from R^c), hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{2-6}alkenyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{2-}

$_{6}$alkynyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{1-6}alkoxy (optionally substituted by one, two or three halogens, cyano, or hydroxyl), R^aR^bN-, R^a-C(O)NR^a-, R^aR^bN-SO_2-, R^aR^bN-C(O)-, R^a-$S(O)_w$- (wherein w is 0, 1 or 2), R^a-SO_2-NR^b-, heteroaryl (optionally substituted by one, two or three moieties each independently selected from R^c, and connected to R^7 through a carbon or heteroatom), heterocycle (optionally substituted by one, two or three moieties each independently selected from R^c, and connected to R^7 through a carbon or heteroatom) or heteroaryloxy (optionally substituted by one, two, or three moieties each independently selected from R^c), or two adjacent R^h groups along with the carbons to which they are attached can be taken together to form a 5- or 6- member heterocyclic or heteroaryl ring optionally substituted with 0, 1 or 2 halogens selected from F or Cl and which may have one or two additional heteroatoms selected from O, S, or N;

p is 0, 1, or 2; and

R^d is selected from the group consisting of: H, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl) or R^aR^bN-C(O)-;

or a pharmaceutically acceptable salts or stereoisomers thereof.

2. The compound of claim 1, wherein:

L^3 is selected from the group consisting of C_1-C_2alkylene, -C(O)-, -CH-C(O)-NH, -$S(O)_w$-, and C_1-C_2alkylene-$S(O)_w$-, wherein w is 0, 1, or 2, and wherein C_1-C_2alkylene is optionally substituted by a substituent selected from the group consisting of: phenyl, biphenyl, phenyloxyphenyl (each optionally substituted by halogen, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl)), mono or bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from O, S, or N and mono or bicyclic heterocycle having 1, 2 or 3 heteroatoms independently selected from O, S, or N; and

R^7 is selected from the group consisting of phenyl, biphenyl, phenyloxyphenyl, and mono or bicyclic heteroaryl or mono or bicyclic heterocycle, wherein the heteroaryl or heterocycle has 1, 2 or 3 heteroatoms independently selected from O, S, or N, and R^7 is optionally substituted by one, two, three or four substituents selected from the group consisting of halogen, cyano, phenyl (optionally substituted by one, two, or three substituents selected from the group consisting of: halogen, methyl, ethyl, propyl, t-butyl, cyano or CF_3), phenyloxy, hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl), C_{1-}

$_{6}$alkoxy (optionally substituted by one, two or three halogens), R^aR^bN-, R^aR^bN-SO_2-, R^a-S(O)$_w$-NR^b- (wherein w is 0, 1 or 2), R^aR^bN-C(O)-, C_{1-6}alkyl-C(O)NR^a-, heteroaryl (optionally substituted by one or two substituents each selected from C_{1-6}alkyl or halogen), or heteroaryloxy (optionally substituted by one or two substituents each selected from C_{1-6}alkyl or halogen).

3. The compound of claim 1 or 2, wherein L^3 is selected from the group consisting of -CH_2-, -$S(O)_2$-, or –C(O)-.

4. The compound of claim 1 or 2, wherein R^7 is selected from the group consisting of phenyl, naphthyl, indanyl, benzodioxole, benzoxazole, benzoisoxazole, benzimidazole, benzotriazole, oxadiazole, indazole, isooxazole, quinoline, isoquinoline, pyridine, pyrazine, pyrimidine, thienyl, thiazole, benzothiopene, indole, benzothiadiazole, pyrazole, or 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine, and R^7 is optionally substituted by one, two, three or four substituents selected from the group consisting of halogen, phenyl (optionally substituted by one, two, or three substituents selected from the group consisting of: halogen, methyl, ethyl, propyl, t-butyl, cyano or CF_3), phenyloxy, hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl), C_{1-6}alkoxy(optionally substituted by one, two or three halogens), R^aR^bN-, R^aR^bN-SO_2-, R^a-S(O)$_w$-NR^b- (wherein w is 0, 1 or 2), R^aR^bN-C(O)-, C_{1-6}alkyl-C(O)NR^a-, heteroaryl (optionally substituted by one or two substituents each selected from C_{1-6}alkyl or halogen), or heteroaryloxy.

5. The compound of any one of claims 1-4, represented by a formula selected from the group consisting of:


,


, and



wherein R^f is independently selected for each occurrence from H, R^aR^bN-, R^aR^bN-C(O)-, phenyoxy, halogen, C_{1-6}alkyl (optionally substituted by one, two or three halogens) and C_{1-6}alkoxy (optionally substituted by one, two or three halogens) wherein R^a and R^b together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring or a 9-10 membered bicyclic heterocyclic ring or spirocycle, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring or 9-10 membered bicyclic heterocyclic ring or spirocycle may optionally be substituted by one or more substituents selected from the group consisting of halogen, cyano, oxo, C_{1-6}alkyl, hydroxyl, $-NH_2$, $-S(O)_w-$ C_{1-6}alkyl (wherein w is 0, 1 or 2) and NH-C(O)-C_{1-6}alkyl.

6. The compound of claim 5, wherein one R_f is a heterocyclic ring selected from piperidinyl, pyrrolidinyl, morpholinyl, and pyrazole.

7. A compound selected from the group consisting of:

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[bis(4-chlorophenyl)methyl]-3-methylpiperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(oxazol-4-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(4-chloro-2-methylphenyl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(1-methyl-1*H*-indazol-5-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(di(pyridin-3-yl)methyl)piperazine-1-carboxylate

1,1,1-trifluoro-3-methoxy-3-oxopropan-2-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate

2-((4-(bis(4-chlorophenyl)methyl)piperazine-1-carbonyl)oxy)-3,3,3-trifluoropropanoic acid

1,1,1-trifluoro-3-(methylamino)-3-oxopropan-2-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-fluoro-4-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-bromo-2-phenoxybenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-fluoro-2-(morpholin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-chloro-4-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-morpholinobenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-chloro-4-morpholinobenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl (2S)-4-[[2-fluoro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl (2S)-2-methyl-4-[[4-(morpholin-4-yl)-2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl (2R)-4-[[2-fluoro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl (2R)-2-methyl-4-[[4-(morpholin-4-yl)-2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-chloro-6-(pyrrolidin-1-yl)phenyl]methyl]piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-chloro-2-(pyrrolidin-1-yl)phenyl]methyl]piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chlorobenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-methyl-4-morpholinobenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-bromo-2-(piperidin-1-yl)benzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-bromo-2-morpholinobenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-methoxy-4-morpholinobenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-morpholinobenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-methyl-4-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-methoxybenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-methylbenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-bromo-2-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-morpholinobenzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-fluoro-4-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-chloro-4-(pyrrolidin-1-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-chloro-6-(morpholin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-chloro-2-(morpholin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(1*H*-pyrazol-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(3-acetamidopyrrolidin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-chloro-2-(morpholin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(4-chloro-1*H*-pyrazol-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(morpholin-4-yl)-2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(morpholin-4-yl)-2-(trifluoromethoxy)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl (2S)-4-[[2-chloro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl (2R)-4-[[2-chloro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate

(S)-1,1,1,3,3,3-hexafluoropropan-2-yl 2-methyl-4-(4-morpholino-2-(trifluoromethoxy)benzyl)piperazine-1-carboxylate

(*R*)-1,1,1,3,3,3-hexafluoropropan-2-yl 2-methyl-4-(4-morpholino-2-(trifluoromethoxy)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-(pyrrolidin-1-yl)-2-(trifluoromethoxy)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-chloro-2-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-fluoro-2-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((3-isopropyl-[1,1'-biphenyl]-4-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-isopropyl-4-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(8-oxa-2-azaspiro[4.5]decan-2-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(4-acetylpiperazin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(1-oxo-2,8-diazaspiro[4.5]decan-8-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(azetidin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-fluoro-4-(1*H*-pyrazol-1-yl)benzyl)piperazine-1-carboxylate

(*R*)-1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(3-acetamidopyrrolidin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

(*S*)-1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(3-acetamidopyrrolidin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(morpholin-4-yl)-2-(propan-2-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-chloro-4-(pyrrolidine-1-carbonyl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-(azetidine-1-carbonyl)-2-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-chloro-2-(morpholine-4-carbonyl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-chloro-2-(pyrrolidine-1-carbonyl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(5*H*-pyrrolo[3,4-*b*]pyridin-6(7*H*)-yl)benzyl)piperazine-1-carboxylate

(*R*)-1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(hexahydropyrrolo[1,2-*a*]pyrazin-2(1*H*)-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(4-(methylsulfonyl)piperazin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((5-(4-methoxyphenyl)isoxazol-3-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((5-phenylisoxazol-3-yl)methyl)piperazine-1-carboxylate,

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl)piperazine-1-carboxylate,

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((1-methyl-3-phenyl-1H-pyrazol-5-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((1-methyl-3-phenyl-1H-pyrazol-4-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((4-bromo-1-methyl-1*H*-pyrazol-5-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-(2-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-phenyl-1-(propan-2-yl)-1H-pyrazol-4-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-(2-chlorophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 3-methyl-4-[(4-phenylphenyl)methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-6-(2-methylphenyl)pyridin-3-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[6-(2-fluorophenyl)-2-methylpyridin-3-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-6-(3-methylphenyl)pyridin-3-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[6-(3-fluorophenyl)-2-methylpyridin-3-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((3-morpholino-[1,1'-biphenyl]-4-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(2-methylpyridin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(3-methylphenyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(2-methylpyridin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(2-methoxy-4-phenylphenyl)methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-(3-fluorophenyl)pyridin-2-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(pyridin-3-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(2,6-dimethylpyridin-4-yl)-2-methylphenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(3-methylpyridin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(3-fluorophenyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(2-fluoro-4-phenylphenyl)methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(2-methyl-4-phenylphenyl)methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(3-methylphenyl)-2-phenoxyphenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(2-methylpyridin-3-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(2-methylpyridin-3-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[6-methyl-5-(2-methylphenyl)pyridin-2-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-(3-fluorophenyl)pyridin-2-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-(3-fluorophenyl)-6-methylpyridin-2-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-(dimethylcarbamoyl)-4-phenylphenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-([4-phenyl-2-[(pyrrolidin-1-yl)carbonyl]phenyl]methyl)piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(6-methylpyridin-2-yl)phenyl]methyl]piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(2,6-dimethylpyridin-4-yl)-2-fluorophenyl]methyl]piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(3-methylpyridin-4-yl)phenyl]methyl]piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(6-methylpyridin-2-yl)phenyl]methyl]piperazine-1-carboxylate
1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[6-methyl-5-(3-methylphenyl)pyridin-2-yl]methyl]piperazine-1-carboxylate
or a pharmaceutically acceptable salt or stereoisomer thereof.

8. A pharmaceutically acceptable composition comprising a compound of any one of claims 1-7, and a pharmaceutically acceptable excipient.

9. Use of a compound of any one of claims 1-7 in the manufacture of a medicament for the treatment of pain.

10. Use of a compound of any one of claims 1-7 in the manufacture of a medicament for the treatment of solid tumor cancer.

11. Use of a compound of any one of claims 1-7 in the manufacture of a medicament for the treatment of obesity or reduction of adipose tissue.

12. Use of a compound of any one of claims 1-7 in the manufacture of a medicament for the treatment of Downs syndrome or Alzheimer's disease.

1. A compound represented by:



(i)

wherein T is CX_3 or  ;

X is selected independently, for each occurrence, from H, F, Cl or Br; wherein at least three occurrences of X are F;

V is O or NR^a;

R^V is selected from the group consisting of hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_3-$_6$cycloalkyl, phenyl, heteroaryl, and heterocyclyl, or when R^a and R^v occur together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring which may have an additional heteroatom selected from O, S, or N; wherein C_1-C_6alkyl, C_2-C_6alkenyl, phenyl, heterocyclic ring and heterocyclyl are optionally substituted by one, two, or three moieties independently selected from the group consisting of halogen, hydroxyl, C_1-C_6alkyl, cyano, phenyl; and

wherein

a)

R_1 and R_2 taken together with the nitrogen to which they are attached form a moiety selected from:

a 4-7 membered heterocyclic ring B having an additional nitrogen; or

a 4-7 membered heterocyclic ring A;

wherein one carbon of ring A has a substituent represented by:



or

;

L^2 is C_1-C_6alkylene or C_1-C_6alkylene-NR^a-;

R^3 and R^5 are each independently selected from phenyl, naphthyl, a mono or bicyclic heteroaryl and a mono or bicyclic heterocycle, wherein the heterocycle or heteroaryl has 1, 2 or 3 heteroatoms independently selected from O, S, or N; and wherein R^3 and R^5 may be independently and optionally substituted by one, two, three or four moieties each independently selected from R^g;

R^4 is selected from the group consisting of H, halogen, hydroxyl, cyano, or C_1-C_6alkoxy;

A is optionally substituted on another carbon by one, two, three or four substituents each independently selected from R^d;

the additional nitrogen of ring B has a substituent represented by:



L^3 is selected from the group consisting of: a bond, C_1-C_6alkylene, -C(O)-, C_1-C_6alkylene-C(O)-, C(O)-C_1-C_6alkylene-, NR^a-C(O)-C_1-C_6alkylene-, C_1-C_6alkylene-O-C(O)-, -$S(O)_w$-, and C_1-C_6alkylene-$S(O)_w$-, wherein w is 0, 1, or 2, and wherein C_1-C_6alkylene is optionally substituted by one or two substituents selected from the group consisting of: halogen, hydroxyl, cyano, and an additional R^7, wherein when L^3 is -$S(O)_w$-, then R^7 is not H;

R^7 is selected from the group consisting of: H, phenyl, naphthyl, mono or bicyclic heteroaryl, and mono or bicyclic heterocyclyl, wherein the heteroaryl or the heterocyclyl has 1, 2 or 3 heteroatoms independently selected from O, S, or N; wherein R^7 is optionally substituted by one, two, three or four moieties independently selected from R^h;

B is optionally substituted on one or more carbons by one, two, three or four moieties each independently selected from R^d;

or

b)

R^1 is $-L^1-R^6$;

R^2 is H or C_1-C_6alkyl;

L^1 is C_1-C_6alkylene or a bond;

R^6 is selected from the group consisting of phenyl, naphthyl, a mono or bicyclic heteroaryl, and a mono or bicyclic heterocycle, wherein the heteroaryl or heterocycle has 1, 2 or 3 heteroatoms independently selected from O, S, or N; and R^6 is optionally substituted by one, two, three or four moieties independently selected from the group consisting of: halogen, phenyl (optionally substituted by one, two or three moieties independently selected from R^c), phenyloxy (optionally substituted by one, two or three moieties independently selected from R^c), anilinyl (optionally substituted on a carbon by one, two or three moieties independently selected from R^c), hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{1-6}alkoxy (optionally substituted by one, two or three halogens, cyano, or hydroxyl), R^aR^bN-, R^aR^bN-SO_2-, R^aR^bN-C(O)-, C_{1-6}alkyl-C(O)NR^a-, R^a-$S(O)_w$-, R^a-$S(O)_w$-NR^b- (wherein w is 0, 1 or 2), heteroaryl (optionally substituted by one, two or three moieties independently selected from R^c), or heteroaryloxy;

R^a and R^b may be independently selected, for each occurrence, from the group consisting of hydrogen and C_{1-3}alkyl; wherein C_{1-3}alkyl may optionally be substituted by one or more substituents selected from halogen, cyano, oxo, hydroxyl, heterocycle, and phenyl;

or R^a and R^b, when they occur together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring or a 9-10 membered bicyclic heterocycle or spirocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring or 9-10 membered bicyclic heterocycle or spirocycle may optionally be substituted by one or more substituents selected from the group consisting of halogen, cyano, oxo, C_{1-6}alkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), hydroxyl, -C(O)-C_{1-6}alkyl, -NH_2, and -NH-C(O)-C_{1-6}alkyl;

R^c is selected from the group consisting of halogen, cyano, hydroxyl, nitro, C_{1-6}alkyl (optionally substituted by one, two, or three halogens, cyano, or hydroxyl), C_{2-6}alkenyl (optionally substituted by one, two, or three halogens), C_{2-6}alkynyl (optionally substituted by one, two, or three halogens), C_{3-6}cycloalkyl, C_{1-6}alkoxy (optionally substituted by one, two, or three halogens), R^aR^bN-, R^aR^bN-SO_2-, R^aR^bN-C(O)-, R^a-C(O)-NR^a-, R^a-C(O)-, R^a-$S(O)_w$-NR^b- (wherein w is 0, 1 or 2), or R^a-$S(O)_w$- (wherein w is 0, 1 or 2);

R^d is selected from the group consisting of: H, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl) or R^aR^bN-C(O)-;

R^g is selected from the group consisting of: halogen, phenyl, phenyloxy, anilinyl, hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{3-6}cycloalkyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{2-6}alkenyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{2-6}alkynyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl) C_{1-6}alkoxy (optionally substituted by one, two or three halogens, cyano, or hydroxyl), R^a-C(O)NR^a-, R^aR^bN-, R^aR^bN-SO_2-, R^a-$S(O)_w$- (wherein w is 0, 1 or 2), R^a-SO_2-NR^b-, R^aR^bN-C(O)-, heterocycle (optionally substituted by one, two or three moieties each independently selected from R^c, and connected to R^3 or R^5 through a carbon or heteroatom) or heteroaryl (optionally substituted by one, two or three moieties each independently selected from R^c, and connected to R^3 or R^5 through a carbon or heteroatom), or two adjacent R^g groups along with the carbons to which they are attached can be taken together to form a 5- or 6- member heterocyclic or heteroaryl ring optionally substituted with 0, 1 or 2 halogens selected from F or Cl and which may have one or two additional heteroatoms selected from O, S, or N;

R^h is selected from the group consisting of: halogen, phenyl (optionally substituted by one, two, or three moieties each independently selected from R^c), phenyloxy (optionally substituted by one, two, or three moieties each independently selected from R^c), hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{2-6}alkenyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{2-6}alkynyl (optionally substituted by one, two or

three halogens, cyano, or hydroxyl), C_{1-6}alkoxy (optionally substituted by one, two or three halogens, cyano, or hydroxyl), R^aR^bN-, R^a-C(O)NR^a-, R^aR^bN-SO_2-, R^aR^bN-C(O)-, R^a-$S(O)_w$- (wherein w is 0, 1 or 2), R^a-SO_2-NR^b-, heteroaryl (optionally substituted by one, two or three moieties each independently selected from R^c, and connected to R^7 through a carbon or heteroatom), heterocycle (optionally substituted by one, two or three moieties each independently selected from R^c, and connected to R^7 through a carbon or heteroatom) or heteroaryloxy (optionally substituted by one, two, or three moieties each independently selected from R^c), or two adjacent R^h groups along with the carbons to which they are attached can be taken together to form a 5- or 6- member heterocyclic or heteroaryl ring optionally substituted with 0, 1 or 2 halogens selected from F or Cl and which may have one or two additional heteroatoms selected from O, S, or N;

and pharmaceutically acceptable salts or stereoisomers thereof.

2. The compound of claim 1, wherein T is CX_3.

3. The compound of claim 1, wherein R^V is selected from the group consisting of methyl, ethyl, *iso*-propyl, *tert*-butyl, benzyl and phenyl.

4. The compound of anyone of claims 1-3, wherein at least four occurrences of X is halogen.

5. The compound of any one of claims 1-4, wherein six occurrences of X is halogen.

6. The compound of any one of claims 1-5, represented by:



.

7. The compound of any one of claims 1-6, wherein R^1 and R^2 taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring B having an additional nitrogen.

8. The compound of any one of claims 1-7, wherein the compound is represented by:



;

wherein p is 0, 1, or 2; and

R^d is selected from the group consisting of: H, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl) or R^aR^bN-C(O)-, wherein L^3 and R^7 are described above

9. The compound of claim 8, wherein:

L^3 is selected from the group consisting of a bond, C_1-C_2alkylene, -C(O)-, -CH-C(O)-NH, -$S(O)_w$-, and C_1-C_2alkylene-$S(O)_w$-, wherein w is 0, 1, or 2, and wherein C_1-C_2alkylene is optionally substituted by a substituent selected from the group consisting of: phenyl, biphenyl, phenyloxyphenyl (each optionally substituted by halogen, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl)), mono or bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from O, S, or N and mono or bicyclic heterocycle having 1, 2 or 3 heteroatoms independently selected from O, S, or N; and

R^7 is selected from the group consisting of phenyl, biphenyl, phenyloxyphenyl, and mono or bicyclic heteroaryl or mono or bicyclic heterocycle, wherein the heteroaryl or heterocycle has 1, 2 or 3 heteroatoms independently selected from O, S, or N, and R^7 is optionally substituted by one, two, three or four substituents selected from the group consisting of halogen, cyano, phenyl (optionally substituted by one, two, or three substituents selected from the group consisting of: halogen, methyl, ethyl, propyl, t-butyl, cyano or CF_3), phenyloxy, hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl), C_{1-6}alkoxy (optionally substituted by one, two or three halogens), R^aR^bN-, R^aR^bN-SO_2-, R^a-$S(O)_w$-NR^b- (wherein w is 0, 1 or 2), R^aR^bN-C(O)-, C_{1-6}alkyl-C(O)NR^a-, heteroaryl (optionally substituted by one or two substituents each selected from C_{1-6}alkyl or halogen), or heteroaryloxy (optionally substituted by one or two substituents each selected from C_{1-6}alkyl or halogen).

10. The compound of claim 8 or 9, wherein L^3 is selected from the group consisting of a bond, $-CH_2$-, -$S(O)_2$-, or –C(O)-.

11. The compound of claim 8 or 9, wherein R^7 is selected from the group consisting of phenyl, naphthyl, indanyl, benzodioxole, benzoxazole, benzoisoxazole, benzimidazole, benzotriazole, oxadiazole, indazole, isooxazole, quinoline, isoquinoline, pyridine, pyrazine, pyrimidine,

thienyl, thiazole, benzothiopene, indole, benzothiadiazole, pyrazole, or 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine, and R^7 is optionally substituted by one, two, three or four substituents selected from the group consisting of halogen, phenyl (optionally substituted by one, two, or three substituents selected from the group consisting of: halogen, methyl, ethyl, propyl, t-butyl, cyano or CF_3), phenyloxy, hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl), C_{1-6}alkoxy(optionally substituted by one, two or three halogens), R^aR^bN-, R^aR^bN-SO_2-, R^a-$S(O)_w$-NR^b- (wherein w is 0, 1 or 2), R^aR^bN-C(O)-, C_{1-6}alkyl-C(O)NR^a-, heteroaryl (optionally substituted by one or two substituents each selected from C_{1-6}alkyl or halogen), or heteroaryloxy.

12. The compound of any one of claims 1-11, wherein R^7 is selected from the group consisting of



wherein

R^e is selected from the group consisting of H, phenyl (optionally substituted by one, two or three substituents each independently selected from halogen, C_{1-6}alkyl (optionally substituted by one, two or three halogens), and C_{1-6}alkoxy (optionally substituted by one, two or three halogens)), and C_{1-6}alkyl (optionally substituted by one, two or three halogens); and

R^i and R^j may be independently selected from the group consisting of: H, CH_3, C_{2-6}alkyl (optionally substituted by one, two or three moieties independently selected from R^c)), phenyl (optionally substituted by one, two or three moieties independently selected from R^c),

and C_{3-6}cycloalkyl (optionally substituted by one, two or three moieties independently selected from R^c) where R^c is described above.

13. The compound of any one of claims 1-12, represented by a formula selected from the group consisting of:





, and



wherein R^f is independently selected for each occurrence from H, R^aR^bN-, R^aR^bN-C(O)-, phenyoxy, halogen, C_{1-6}alkyl (optionally substituted by one, two or three halogens) and C_{1-6}alkoxy (optionally substituted by one, two or three halogens) wherein R^a and R^b together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring or a 9-10 membered bicyclic heterocyclic ring or spirocycle, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring or 9-10 membered bicyclic heterocyclic ring or spirocycle may optionally be substituted by one or more substituents selected from the group consisting of halogen, cyano, oxo, C_{1-6}alkyl, hydroxyl, -NH_2, -$S(O)_w$- C_{1-6}alkyl (wherein w is 0, 1 or 2) and NH-C(O)-C_{1-6}alkyl.

14. The compound of claim 13, wherein one R_f is a heterocyclic ring selected from piperidinyl, pyrrolidinyl, morpholinyl, and pyrazole.

15. The compound of any one of claims 1-7, wherein L^3 is –CH-R^{10}, wherein R^{10} selected from the group consisting of phenyl, naphthyl, indanyl, benzodioxole, benzoxazole, benzoisoxazole, benzimidazole, benzotriazole, oxadiazole, indazole, isooxazole, quinoline, isoquinoline, pyridine, pyrazine, pyrimidine, thienyl, thiazole, benzothiopene, indole, benzothiadiazole, pyrazole, or 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine , wherein R^{10} may be optionally substituted by one, two or three moieties each independently selected from the group consisting of halogen, phenyl (optionally substituted by halogen, cyano, methyl or CF_3), phenyloxy

(optionally substituted by halogen, cyano, methyl or CF_3), hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl), C_{1-6}alkoxy (optionally substituted by one, two or three halogens, cyano or hydroxyl), R^aR^bN-, R^aR^bN-SO_2-, R^a-$S(O)_w$-NR^b- (wherein w is 0, 1 or 2), R^aR^bN-C(O)-, C_{1-6}alkyl-C(O)NR^a-, heteroaryl (optionally substituted by C_{1-6}alkyl), or heteroaryloxy.

16. The compound of claim 15, wherein R^{10} is selected from the group consisting of



wherein

R^c is selected from the group consisting of H, phenyl (optionally substituted by one, two or three substituents each independently selected from halogen, C_{1-6}alkyl (optionally substituted by one, two or three halogens), and C_{1-6}alkoxy (optionally substituted by one, two or three halogens)), and C_{1-6}alkyl (optionally substituted by one, two or three halogens);

17. The compound of claim 15, wherein R^7 is selected from the group consisting of phenyl, naphthyl, indanyl, benzodioxole, benzoxazole, benzoisoxazole, benzimidazole, benzotriazole, oxadiazole, indazole, isooxazole, quinoline, isoquinoline, pyridine, pyrazine, pyrimidine, thienyl, thiazole, benzothiopene, indole, benzothiadiazole, pyrazole, or 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine, and R^7 is optionally substituted by one, two or three substituents selected from the group consisting of halogen, phenyl (optionally substituted by one, two, or three substituents selected from the group consisting of: halogen, methyl, ethyl, propyl, t-butyl, cyano or CF_3), phenyloxy, hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl), C_{1-6}alkoxy, R^aR^bN-, R^aR^bN-SO_2-, R^a-$S(O)_w$-NR^b- (wherein w is 0, 1 or 2), R^aR^bN-C(O)-, C_{1-6}alkyl-C(O)NR^a-, heteroaryl (optionally substituted by one or two substituents each selected from C_{1-6}alkyl or halogen), or heteroaryloxy.

18. The compound of any one of claims 1-6, wherein the compound is represented by:



wherein:

R^2 is H or C_1-C_3alkyl;

L^1 is $-CH_2-$ or $-CH_2-CH_2-$; and

R^6 is selected from the group consisting of phenyl, naphthyl, indanyl, benzodioxole, benzoxazole, benzoisoxazole, benzimidazole, benzotriazole, oxadiazole, indazole, isooxazole, quinoline, isoquinoline, pyridine, pyrazine, pyrimidine, thienyl, thiazole, benzothiopene, indole, benzothiadiazole, pyrazole, or 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine , wherein R^6 may be optionally substituted by one, two, three or four moieties each independently selected from the group consisting of halogen, phenyl (optionally substituted by halogen, cyano, methyl or CF_3), phenyloxy, hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl), C_{1-6}alkoxy (optionally substituted by one, two or three halogens, or hydroxyl), R^aR^bN-, R^aR^bN-SO_2-, R^a-$S(O)_w$- (wherein w is 0, 1 or 2), R^a-$S(O)_w$-NR^b- (wherein w is 0, 1 or 2), R^aR^bN-C(O)-, C_{1-6}alkyl-C(O)NR^a-, heteroaryl (optionally substituted by C_{1-6}alkyl), or heteroaryloxy.

19. The compound of claim 18, wherein R^6 is phenyl, optionally substituted by halogen, cyano, hydroxyl, methoxy, pyridine (optionally substituted by methyl), phenyl, or phenyloxy.

20. The compound of claim 18 or 19, wherein R^2 is methyl.

21. The compound of any one of claims 18-20, wherein L^1 is $-CH_2-$.

22. The compound of any one of claims 18-20, wherein R^6 is selected from the group consisting of:

 ,  , and  .

23. The compound of any one of claims 1-6, wherein R^1 and R^2 taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring A wherein one carbon of ring A has a substituent represented by:

 or  .

24. The compound of claim 23, wherein the compound is represented by:




or ;

wherein p is 0, 1, or 2; and

R^d is selected from the group consisting of: H, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl) or R^aR^bN-C(O)-.

25. The compound of claim 23 or 24, wherein R^3 and R^5 are each independently selected from the group consisting of:




, , and .

26. The compound of any one of claims 23-25, wherein R^4 is selected from the group consisting of H, hydroxyl and methoxy.

27. A compound represented by:



wherein:

p is 0, 1, or 2;

R^d is selected from the group consisting of: H, C_{1-6}alkyl (optionally substituted by one, two or three halogens, or hydroxyl) or R^aR^bN-C(O)-.

L^3 is selected from the group consisting of: a bond, C_1-C_6alkylene, -C(O)-, C_1-C_6alkylene-C(O)-, C_1-C_6alkylene-O-C(O)-, NR^a-C(O)- C_1-C_6alkylene-, -$S(O)_w$-, and C_1-C_6alkylene-$S(O)_w$-, wherein w is 0, 1, or 2, and wherein C_1-C_6alkylene is optionally substituted

by one or two substituents selected from the group consisting of: halogen, hydroxyl, cyano, and an additional R^7;

R^7 is selected from the group consisting of: H, phenyl, naphthyl, mono or bicyclic heteroaryl or mono or bicyclic heterocycle, wherein the heteroaryl or heterocycle has 1, 2 or 3 heteroatoms independently selected from O, S, or N; wherein R^7 is optionally substituted by one, two, three or four moieties independently selected from the group consisting of halogen, phenyl (optionally substituted by one, two, or three moieties each independently selected from R^c), phenyloxy (optionally substituted by one, two, or three moieties each independently selected from R^c), hydroxyl, cyano, C_{1-6}alkyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{2-6}alkenyl (optionally substituted by one, two or three halogens, cyano, or hydroxyl), C_{1-6}alkoxy (optionally substituted by one, two or three halogens, cyano, or hydroxyl), R^aR^bN-, R^a-C(O)NR^a-, R^aR^bN-SO_w- (wherein w is 0, 1 or 2); R^aR^bN-C(O)-, R^a-$S(O)_w$- (wherein w is 0, 1 or 2), R^a-$S(O)_w$-NR^b- (wherein w is 0, 1 or 2), heteroaryl (optionally substituted by one, two or three moieties each independently selected from R^c) or heteroaryloxy (optionally substituted by one, two, or three moieties each independently selected from R^c);

R^a and R^b may be independently selected, for each occurrence, from the group consisting of hydrogen and C_{1-3}alkyl; wherein C_{1-3}alkyl may optionally be substituted by one or more substituents selected from halogen, cyano, oxo , hydroxyl, heterocycle, and phenyl;

or R^a and R^b, when they occur together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring or a 9-10 membered bicyclic heterocycle or spirocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring or 9-10 membered bicyclic heterocycle or spirocycle may optionally be substituted by one or more substituents selected from the group consisting of halogen, cyano, oxo, C_{1-6}alkyl, -$S(O)_w$-C_{1-6}alkyl (where w is 0, 1 or 2), hydroxyl, -NH_2, and NH-C(O)-C_{1-6}alkyl;

R^c is selected from the group consisting of halogen, cyano, hydroxyl, nitro, C_{1-6}alkyl (optionally substituted by one, two, or three halogens, cyano, or hydroxyl), C_{2-6}alkenyl (optionally substituted by one, two, or three halogens), C_{3-6}cycloalkyl, C_{1-6}alkoxy (optionally

substituted by one, two, or three halogens), R^aR^bN-, R^aR^bN-SO_2-, R^aR^bN-C(O)-, R^a-$C(O)_w$-NR^a-, R^a-C(O)-, R^a-$S(O)_w$-NR^b- (wherein w is 0, 1 or 2), or R^a-$S(O)_w$- (wherein w is 0, 1 or 2);

T is CX_3 or  ;

X is independently for each occurrence halogen or H;

V is O or NR^a;

R^V is selected from the group consisting of hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_3-$_6$cycloalkyl, phenyl, heteroaryl, and heterocyclyl, or when R^a and R^v occur together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring which may have an additional heteroatom selected from O, S, or N; wherein C_1-C_6alkyl, C_2-C_6alkenyl, phenyl, heterocyclic ring and heterocyclyl are optionally substituted by one, two, or three moieties independently selected from the group consisting of halogen, hydroxyl, C_1-C_6alkyl, cyano, phenyl;

or pharmaceutically acceptably salts or stereoisomers thereof.

28. A compound selected from the group consisting of:



,


,



,


,

4  ,  ,

5  ,  ,

6  ,  ,

7  ,  ,

8  ,  ,

 ,  ,  ,

 ,  ,  ,

 ,  ,

 ,  ,

 ,  ,

 ,  ,

 ,  ; and

stereoisomers thereof, or pharmaceutically acceptable salts thereof.

29. A compound selected from the group consisting of:

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[bis(4-chlorophenyl)methyl]-3-methylpiperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(oxazol-4-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(4-chloro-2-methylphenyl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(1-methyl-1*H*-indazol-5-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(di(pyridin-3-yl)methyl)piperazine-1-carboxylate

1,1,1-trifluoro-3-methoxy-3-oxopropan-2-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate

2-((4-(bis(4-chlorophenyl)methyl)piperazine-1-carbonyl)oxy)-3,3,3-trifluoropropanoic acid

1,1,1-trifluoro-3-(methylamino)-3-oxopropan-2-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate

Methyl 3,3,3-trifluoro-2-((methyl(phenethyl)carbamoyl)oxy)propanoate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-fluoro-4-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-bromo-2-phenoxybenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-fluoro-2-(morpholin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-chloro-4-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-chloro-4-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl (2S)-4-[[2-fluoro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl (2S)-2-methyl-4-[[4-(morpholin-4-yl)-2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl (2R)-4-[[2-fluoro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl (2R)-2-methyl-4-[[4-(morpholin-4-yl)-2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-chloro-6-(pyrrolidin-1-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-chloro-2-(pyrrolidin-1-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-methyl-4-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-bromo-2-(piperidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-bromo-2-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-methoxy-4-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-methyl-4-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-methoxybenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-methylbenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-bromo-2-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-fluoro-4-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-chloro-4-(pyrrolidin-1-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-chloro-6-(morpholin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-chloro-2-(morpholin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(1*H*-pyrazol-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(3-acetamidopyrrolidin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-chloro-2-(morpholin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-morpholinobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(4-chloro-1*H*-pyrazol-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(morpholin-4-yl)-2-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(morpholin-4-yl)-2-(trifluoromethoxy)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl (2S)-4-[[2-chloro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl (2R)-4-[[2-chloro-4-(morpholin-4-yl)phenyl]methyl]-2-methylpiperazine-1-carboxylate

(S)-1,1,1,3,3,3-hexafluoropropan-2-yl 2-methyl-4-(4-morpholino-2-(trifluoromethoxy)benzyl)piperazine-1-carboxylate

(*R*)-1,1,1,3,3,3-hexafluoropropan-2-yl 2-methyl-4-(4-morpholino-2-(trifluoromethoxy)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-(pyrrolidin-1-yl)-2-(trifluoromethoxy)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-chloro-2-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-fluoro-2-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((3-isopropyl-[1,1'-biphenyl]-4-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-isopropyl-4-(pyrrolidin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(8-oxa-2-azaspiro[4.5]decan-2-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(4-acetylpiperazin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(1-oxo-2,8-diazaspiro[4.5]decan-8-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(azetidin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-fluoro-4-(1*H*-pyrazol-1-yl)benzyl)piperazine-1-carboxylate

(*R*)-1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(3-acetamidopyrrolidin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

(*S*)-1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(3-acetamidopyrrolidin-1-yl)-4-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(morpholin-4-yl)-2-(propan-2-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-chloro-4-(pyrrolidine-1-carbonyl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-(azetidine-1-carbonyl)-2-chlorobenzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-chloro-2-(morpholine-4-carbonyl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-chloro-2-(pyrrolidine-1-carbonyl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(5*H*-pyrrolo[3,4-*b*]pyridin-6(7*H*)-yl)benzyl)piperazine-1-carboxylate

(*R*)-1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(hexahydropyrrolo[1,2-*a*]pyrazin-2(1*H*)-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-(4-chloro-2-(4-(methylsulfonyl)piperazin-1-yl)benzyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((5-(4-methoxyphenyl)isoxazol-3-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((5-phenylisoxazol-3-yl)methyl)piperazine-1-carboxylate,

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl)piperazine-1-carboxylate,

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((1-methyl-3-phenyl-1H-pyrazol-5-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((1-methyl-3-phenyl-1H-pyrazol-4-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((4-bromo-1-methyl-1*H*-pyrazol-5-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-(2-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-phenyl-1-(propan-2-yl)-1H-pyrazol-4-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[3-(2-chlorophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 3-methyl-4-[(4-phenylphenyl)methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-6-(2-methylphenyl)pyridin-3-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[6-(2-fluorophenyl)-2-methylpyridin-3-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-6-(3-methylphenyl)pyridin-3-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[6-(3-fluorophenyl)-2-methylpyridin-3-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-((3-morpholino-[1,1'-biphenyl]-4-yl)methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(2-methylpyridin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(3-methylphenyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(2-methylpyridin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(2-methoxy-4-phenylphenyl)methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-(3-fluorophenyl)pyridin-2-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(pyridin-3-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(2,6-dimethylpyridin-4-yl)-2-methylphenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(3-methylpyridin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(3-fluorophenyl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(2-fluoro-4-phenylphenyl)methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[(2-methyl-4-phenylphenyl)methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(3-methylphenyl)-2-phenoxyphenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(2-methylpyridin-3-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(2-methylpyridin-3-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[6-methyl-5-(2-methylphenyl)pyridin-2-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-(3-fluorophenyl)pyridin-2-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[5-(3-fluorophenyl)-6-methylpyridin-2-yl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-(dimethylcarbamoyl)-4-phenylphenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-([4-phenyl-2-[(pyrrolidin-1-yl)carbonyl]phenyl]methyl)piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-4-(6-methylpyridin-2-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(2,6-dimethylpyridin-4-yl)-2-fluorophenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(3-methylpyridin-4-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-fluoro-4-(6-methylpyridin-2-yl)phenyl]methyl]piperazine-1-carboxylate

1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[6-methyl-5-(3-methylphenyl)pyridin-2-yl]methyl]piperazine-1-carboxylate

And pharmaceutically acceptable salt or stereoisomers thereofy.

30. A pharmaceutically acceptable composition comprising a compound of anyone of claims 1-29, and a pharmaceutically acceptable excipient.

31. Use of an effective amount of a compound of any one of claims 1-29, in the manufacture of a medicament for treating pain.

32. Use of an effective amount of a compound of any one of claims 1-29, in the manufacture of a medicament for treating a solid tumor cancer in a patient in need thereof.

33. Use of an effective amount of a compound of any one of claims 1-29, in the manufacture of a medicament for treating obesity or reducing adipose tissue in a patient in need thereof.

34. Use of an effective amount of a compound of any one of claims 1-29, in the manufacture of a medicament for treating or ameliorating Downs syndrome or Alzheimer's disease.